Table IV.

Summary of during-treatment AEs of special interest (safety population^∗)

Special interest group (preferred term), no. (%)	Placebo (n = 82)	GSK3772847 (n = 83)
Systemic allergic/hypersensitivity and nonallergic reactions	2 (2)	6 (7)
Rhinitis allergic	2 (2)	0
Swelling face	0	2 (2)
Urticaria	0	2 (2)
Anaphylactic shock	0	1 (1)
Angioedema	0	1 (1)
Bronchospasm	0	1 (1)
Eye swelling	0	1 (1)
Rash	0	1 (1)
All infections	16 (20)	15 (18)
Nasopharyngitis	4 (5)	4 (5)
Influenza	4 (5)	1 (1)
Upper respiratory tract infection	1 (1)	4 (5)
Respiratory tract infection viral	2 (2)	2 (2)
Rhinitis	2 (2)	2 (2)
Sinusitis	2 (2)	2 (2)
Pharyngitis	2 (2)	0
Conjunctivitis	0	1 (1)
Ear infection	1 (1)	0
Pharyngotonsillitis	1 (1)	0
Pneumonia	1 (1)	0
Upper respiratory tract infection bacterial	1 (1)	0
Serious infections	1 (1)	0
Pneumonia	1 (1)	0
Cardiac disorders	6 (7)	8 (10)
Ventricular tachycardia	3 (4)	1 (1)
Dizziness	0	2 (2)
Rhythm idioventricular	1 (1)	1 (1)
Ventricular extrasystoles	1 (1)	1 (1)
Chest discomfort	0	1 (1)
Peripheral swelling	0	1 (1)
Presyncope	0	1 (1)
Sinus tachycardia	1 (1)	0
Serious cardiac, vascular, and thromboembolic events	0	1 (1)
Anaphylactic shock	0	1 (1)

During-treatment AE is defined as an AE the onset of which occurs from the date of initiation of the study treatment to 28 days after the study treatment has been stopped.

^∗Preferred terms may contribute to more than 1 special interest group; AEs of special interest were counted for each special interest group in which they appear.